MORPHOSYS AG
MORPHOSYS AG (DELISTED)
Share · DE0006632003 · 663200 (XETR)
Overview Financial Indicators
No Price
n/a

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
- - - - 0,00 % 0,52 % -39,39 %

Company Profile for MORPHOSYS AG Share

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.

Invested Funds

The following funds have invested in: MORPHOSYS AG invested:

Fund
iShares TecDAX® UCITS ETF (DE) EUR (Acc)
Vol. in million
12.878,53
Percentage (%)
1,18 %
Fund
iShares TecDAX® UCITS ETF (DE) EUR (Dist)
Vol. in million
3,72
Percentage (%)
1,18 %
Fund
iShares EURO STOXX Small UCITS ETF EUR (Dist)
Vol. in million
6.502,84
Percentage (%)
0,51 %
Fund
iShares MDAX® UCITS ETF (DE) EUR (Dist)
Vol. in million
12,61
Percentage (%)
0,46 %
Fund
iShares MSCI EMU Small Cap UCITS ETF EUR (Acc)
Vol. in million
2.364,24
Percentage (%)
0,28 %

Company Data

Name MORPHOSYS AG
Company MorphoSys AG
Website https://www.morphosys.com
Primary Exchange XETR XETRA
WKN 663200
ISIN DE0006632003
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Mr. Arkadius Pichota M.B.A., Ph.D.
Market Capitalization 3 Mrd.
Country Germany
Currency EUR
Employees 0,5 T
Address Semmelweisstrasse 7, 82152 Planegg
IPO Date 1999-03-10

Ticker Symbols

Name Symbol
Frankfurt MOR.F
XETRA MOR.DE

More Shares

Investors who MORPHOSYS AG hold also have the following shares in their portfolio:
ALPHABET INC - CLASS A
ALPHABET INC - CLASS A Share
AMAZON.CO INC
AMAZON.CO INC Share
B2GOLD CORP
B2GOLD CORP Share
BAYER AG
BAYER AG Share
ERSTE GR.BK. 24/26 MTN
ERSTE GR.BK. 24/26 MTN Bond
INFINEON TECHNOLOGIESLOGIES AG
INFINEON TECHNOLOGIESLOGIES AG Share
INTEL CORP
INTEL CORP Share
ISHSIV-MSCI CHINA DL A
ISHSIV-MSCI CHINA DL A ETF
JOHN DEERE C 24/31 MTN
JOHN DEERE C 24/31 MTN Bond
META PLATFORMS INC
META PLATFORMS INC Share
MICROSOFT CORP
MICROSOFT CORP Share
PAYPAL INC
PAYPAL INC Share
SAP SE
SAP SE Share
WALT DISNEY INC
WALT DISNEY INC Share
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025